相关实验视频

Updated: May 21, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

针对肝脏以外的PCSK9:实验和临床研究的证据

Lorenzo Da Dalt¹, Andrea Baragetti¹, Giuseppe Danilo Norata¹

¹Department of Pharmacological Sciences 'Rodolfo Paoletti', University of Milan, Milano, Italy.

Expert opinion on therapeutic targets

|March 20, 2025

概括

遗传PCSK9缺乏与糖尿病和免疫变化有关,但这些影响在向PCSK9的药物中没有出现. 终身遗传抑制可能会导致与短期药理学不同的适应.

科学领域:

心血管医学心血管医学
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

抑制9型蛋白转化酶 (PCSK9) 抑制增加了LDL受体循环,增强了LDL颗粒的清除.
PCSK9在各种组织中合成,包括大脑,胰腺,心脏和免疫细胞.
了解基因与药物抑制对肝外PCSK9的影响至关重要.

研究的目的:

为了调查遗传和药理学PCSK9抑制效应之间的差异.
为了确定在遗传研究中观察到的肝外效应是否被PCSK9向疗法复制.

主要方法:

对PCSK9缺陷的遗传研究的审查.
对PCSK9单克隆抗体 (mAbs) 和基因沉默的临床试验数据和现实世界的证据的分析.
终身遗传抑制与短期药物抑制的比较.

主要成果:

遗传PCSK9缺乏与新发糖尿病,宫外脂肪和免疫炎症反应减少的风险增加有关.
在使用PCSK9 mAbs或基因沉默的临床试验中没有观察到这些不良反应.
药理上抑制PCSK9 (长达12年) 主要导致显著的LDL-C降低和心血管事件的减少.

结论:

来自遗传PCSK9抑制的终身生物适应可能与短期药理效应有所不同.
目前的PCSK9药理有效地降低了LDL-C和心血管风险,在观察到的时间范围内没有明显的肝外不良影响.

关键词:

在PCSK9中心血管疾病心血管疾病胆固醇胆固醇胆固醇是一种一个单克隆抗体.如果RNAss.

更多相关视频

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...